前部ぶどう膜炎の世界市場レポート 2025年

前部ぶどう膜炎の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR11.6％で8億9,000万米ドルに成長します。予測期間における成長の背景には、自己免疫疾患に対する認識の高まり、生物学的製剤の採用の増加、炎症性疾患の有病率の増加、ヘルスケア支出の増加、個別化医療に関する研究の進行などがあります。主な動向としては、新規生物学的製剤の進歩、コルチコステロイド送達システムの採用、高度診断画像の革新、個別化医療アプローチ、標的免疫調節薬、低侵襲手術技術の使用、デジタルヘルスツールの開発などが挙げられます。

自己免疫疾患の有病率の増加は、前部ぶどう膜炎市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が健康な細胞や組織を異物の脅威と誤認して攻撃することで発生します。この異常な反応は、様々な臓器やシステムにおいて炎症や損傷を引き起こします。自己免疫疾患の増加は、遺伝的素因、環境要因、ライフスタイルの変化、より良い診断につながる認知度の向上に起因しています。前部ぶどう膜炎は、関節リウマチや強直性脊椎炎などの自己免疫疾患に関連する一般的な炎症性眼疾患です。例えば、2024年11月、ドイツを拠点とする団体であるVersorgungsatlas.deは、2022年に7,324万1,305人の被保険者のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断され、その結果、生の有病率は8.61％と報告しました。その結果、自己免疫疾患の罹患率の増加が前部ぶどう膜炎市場の拡大に拍車をかけています。

前部ぶどう膜炎市場の主要企業は、患者のコンプライアンスを改善し、ドラッグデリバリーを強化し、副作用の少ない炎症を抑える点眼薬などの革新的な製剤を開発することで、治療アプローチを進めています。点眼薬は、炎症の抑制、疼痛の緩和、合併症の予防など、前部ぶどう膜炎の管理に広く使用されています。例えば、2024年1月、イスラエルを拠点とする製薬会社Tarsier Pharma Ltd.は、米国食品医薬品局（FDA）より、Tarsier-04フェーズ3試験の臨床試験プロトコールおよび統計解析計画に関する特別プロトコル評価（SPA）の承認を取得しました。本試験は、ぶどう膜緑内障を含む非感染性ぶどう膜炎に対するTRS01点眼薬の有効性を評価することを目的としています。Tarsier-04試験は、米国において最大300名の患者を登録する多施設、無作為化、二重マスク、アクティブコントロール試験であり、TRS01の安全性と有効性、特に緑内障のリスクを増加させることなく炎症をコントロールすることを実証することを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界前部ぶどう膜炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の前部ぶどう膜炎市場：成長率分析
• 世界の前部ぶどう膜炎市場の実績：規模と成長, 2019-2024
• 世界の前部ぶどう膜炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界前部ぶどう膜炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の前部ぶどう膜炎市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物療法
• 外科的治療
• 生物学的療法
• 世界の前部ぶどう膜炎市場診断方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臨床診断
• 診断画像
• バイオマーカー
• 世界の前部ぶどう膜炎市場原因別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 感染性
• 非感染性
• 世界の前部ぶどう膜炎市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 外来手術センター
• 世界の前部ぶどう膜炎市場薬物療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 非ステロイド性抗炎症薬（NSAID）
• 免疫抑制薬
• 世界の前部ぶどう膜炎市場、外科的治療の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 白内障手術
• 緑内障手術
• 硝子体切除術
• 世界の前部ぶどう膜炎市場生物学的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍壊死因子（TNF）阻害剤
• インターロイキン-6（IL-6）阻害剤
• モノクローナル抗体

第7章 地域別・国別分析

• 世界の前部ぶどう膜炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の前部ぶどう膜炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 前部ぶどう膜炎市場：競合情勢
• 前部ぶどう膜炎市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Aerie Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Regeneron Pharmaceuticals Inc.
• UCB S.A.
• Bausch & Lomb Incorporated
• Cipla Ltd.
• Hikma Pharmaceuticals PLC
• Cadila Pharmaceuticals Ltd.
• Santen Pharmaceutical Co. Ltd.
• HanAll Biopharma Co. Ltd.
• EyePoint Pharmaceuticals Inc.
• Kiora Pharmaceuticals Inc.
• Clearside Biomedical Inc.
• Oculis SA
• Aldeyra Therapeutics Inc.
• Lux Biosciences Inc.
• Tarsier Pharma Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 前部ぶどう膜炎市場2029：新たな機会を提供する国
• 前部ぶどう膜炎市場2029：新たな機会を提供するセグメント
• 前部ぶどう膜炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anterior uveitis is an inflammatory condition affecting the eye's middle layer, including the iris and ciliary body. It can result from eye trauma, such as a direct injury or a foreign object, or be associated with systemic conditions such as rheumatoid arthritis, syphilis, tuberculosis, sarcoidosis, or viral infections (herpes simplex, herpes zoster, cytomegalovirus). In some cases, the cause remains idiopathic, with no identifiable underlying factor.

The primary treatment options for anterior uveitis include pharmacological therapies, surgical interventions, and biologic treatments. Pharmacological therapies involve medications to reduce inflammation and manage symptoms. Diagnosis is conducted through clinical evaluation, diagnostic imaging, and biomarker testing. The condition may have infectious or non-infectious origins and is managed in hospitals, clinics, and ambulatory surgical centers.

The anterior uveitis market research report is one of a series of new reports from The Business Research Company that provides anterior uveitis market statistics, including the anterior uveitis industry's global market size, regional shares, competitors with a anterior uveitis market share, detailed anterior uveitis market segments, market trends and opportunities, and any further data you may need to thrive in the anterior uveitis industry. This anterior uveitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anterior uveitis market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.58 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to the increasing prevalence of autoimmune disorders, greater awareness of eye health, improved access to healthcare, the growing use of corticosteroids and biologics, expanding research on immunological pathways, and a rising aging population.

The anterior uveitis market size is expected to see rapid growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing awareness of autoimmune diseases, the rising adoption of biologic therapies, a growing prevalence of inflammatory conditions, higher healthcare expenditure, and ongoing research into personalized medicine. Major trends include advancements in novel biologics, the adoption of corticosteroid delivery systems, innovations in advanced diagnostic imaging, personalized medicine approaches, targeted immunomodulators, the use of minimally invasive surgical techniques, and the development of digital health tools.

The increasing prevalence of autoimmune diseases is expected to drive growth in the anterior uveitis market. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells and tissues, perceiving them as foreign threats. This abnormal response leads to inflammation and damage in various organs and systems. The rise in autoimmune diseases is attributed to genetic predisposition, environmental factors, lifestyle changes, and improved awareness leading to better diagnosis. Anterior uveitis is a common inflammatory eye condition associated with autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. As a result, the growing incidence of autoimmune diseases is fueling the expansion of the anterior uveitis market.

Leading companies in the anterior uveitis market are advancing treatment approaches by developing innovative drug formulations such as eye drops to improve patient compliance, enhance drug delivery, and reduce inflammation with fewer side effects. Eye drops are widely used to manage anterior uveitis by controlling inflammation, alleviating pain, and preventing complications. For instance, in January 2024, Tarsier Pharma Ltd., an Israel-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the clinical trial protocol and statistical analysis plan of the Tarsier-04 Phase 3 trial. This trial aims to assess the effectiveness of TRS01 eye drops in treating non-infectious uveitis, including uveitic glaucoma. The Tarsier-04 trial is a multicenter, randomized, double-masked, active-controlled study enrolling up to 300 patients in the U.S., with the objective of demonstrating TRS01's safety and efficacy, particularly in controlling inflammation without increasing the risk of glaucoma.

In January 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Oxular Limited for an undisclosed amount. This acquisition enhances Regeneron's capabilities in ocular gene therapies by integrating an advanced delivery device, expediting the development of clinical treatments. By leveraging Oxular's proprietary technologies, Regeneron aims to improve therapeutic precision and drive innovation in eye care. Oxular Limited is a UK-based biotech company specializing in drug and device treatments for retinal disorders, including anterior uveitis.

Major players in the anterior uveitis market are AbbVie Inc., Novartis AG, Amgen Inc., Aerie Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Bausch & Lomb Incorporated, Cipla Ltd., Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals Ltd., Santen Pharmaceutical Co. Ltd., HanAll Biopharma Co. Ltd., EyePoint Pharmaceuticals Inc., Kiora Pharmaceuticals Inc., Clearside Biomedical Inc., Oculis SA, Aldeyra Therapeutics Inc., Lux Biosciences Inc., Tarsier Pharma Ltd., Xoma Corporation.

North America was the largest region in the anterior uveitis market in 2024. The regions covered in anterior uveitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anterior uveitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anterior uveitis market consists of revenues earned by entities by provide services such as slit-lamp examinations, optical coherence tomography (OCT), ultrasound biomicroscopy, corticosteroid administration, and glaucoma management. The market value includes the value of related goods sold by the service provider or included within the service offering. The anterior uveitis market also includes sales of corticosteroids (topical and systemic), non-steroidal anti-inflammatory drugs (NSAIDS), and immunosuppressive drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anterior Uveitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anterior uveitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anterior uveitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anterior uveitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Pharmacological Treatments; Surgical Treatments; Biologic Therapy
• 2) By Diagnosis Method: Clinical Diagnosis; Diagnostic Imaging; Biomarkers
• 3) By Cause: Infectious; Non-Infectious
• 4) By End-User: Hospitals And Clinics; Ambulatory Surgical Centers
• Subsegments:
• 1) By Pharmacological Treatments: Corticosteroids; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Immunosuppressive Drugs
• 2) By Surgical Treatments: Cataract Surgery; Glaucoma Surgery; Vitrectomy
• 3) By Biologic Therapy: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; Monoclonal Antibodies
• Companies Mentioned: AbbVie Inc.; Novartis AG; Amgen Inc.; Aerie Pharmaceuticals Inc.; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anterior Uveitis Market Characteristics

3. Anterior Uveitis Market Trends And Strategies

4. Anterior Uveitis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Anterior Uveitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anterior Uveitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anterior Uveitis Market Growth Rate Analysis
• 5.4. Global Anterior Uveitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anterior Uveitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anterior Uveitis Total Addressable Market (TAM)

6. Anterior Uveitis Market Segmentation

• 6.1. Global Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacological Treatments
• Surgical Treatments
• Biologic Therapy
• 6.2. Global Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinical Diagnosis
• Diagnostic Imaging
• Biomarkers
• 6.3. Global Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infectious
• Non-Infectious
• 6.4. Global Anterior Uveitis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Ambulatory Surgical Centers
• 6.5. Global Anterior Uveitis Market, Sub-Segmentation Of Pharmacological Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Immunosuppressive Drugs
• 6.6. Global Anterior Uveitis Market, Sub-Segmentation Of Surgical Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cataract Surgery
• Glaucoma Surgery
• Vitrectomy
• 6.7. Global Anterior Uveitis Market, Sub-Segmentation Of Biologic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Necrosis Factor (TNF) Inhibitors
• Interleukin-6 (IL-6) Inhibitors
• Monoclonal Antibodies

7. Anterior Uveitis Market Regional And Country Analysis

• 7.1. Global Anterior Uveitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anterior Uveitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anterior Uveitis Market

• 8.1. Asia-Pacific Anterior Uveitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anterior Uveitis Market

• 9.1. China Anterior Uveitis Market Overview
• 9.2. China Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anterior Uveitis Market

• 10.1. India Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anterior Uveitis Market

• 11.1. Japan Anterior Uveitis Market Overview
• 11.2. Japan Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anterior Uveitis Market

• 12.1. Australia Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anterior Uveitis Market

• 13.1. Indonesia Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anterior Uveitis Market

• 14.1. South Korea Anterior Uveitis Market Overview
• 14.2. South Korea Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anterior Uveitis Market

• 15.1. Western Europe Anterior Uveitis Market Overview
• 15.2. Western Europe Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anterior Uveitis Market

• 16.1. UK Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anterior Uveitis Market

• 17.1. Germany Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anterior Uveitis Market

• 18.1. France Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anterior Uveitis Market

• 19.1. Italy Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anterior Uveitis Market

• 20.1. Spain Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anterior Uveitis Market

• 21.1. Eastern Europe Anterior Uveitis Market Overview
• 21.2. Eastern Europe Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anterior Uveitis Market

• 22.1. Russia Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anterior Uveitis Market

• 23.1. North America Anterior Uveitis Market Overview
• 23.2. North America Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anterior Uveitis Market

• 24.1. USA Anterior Uveitis Market Overview
• 24.2. USA Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anterior Uveitis Market

• 25.1. Canada Anterior Uveitis Market Overview
• 25.2. Canada Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anterior Uveitis Market

• 26.1. South America Anterior Uveitis Market Overview
• 26.2. South America Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anterior Uveitis Market

• 27.1. Brazil Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anterior Uveitis Market

• 28.1. Middle East Anterior Uveitis Market Overview
• 28.2. Middle East Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anterior Uveitis Market

• 29.1. Africa Anterior Uveitis Market Overview
• 29.2. Africa Anterior Uveitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anterior Uveitis Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anterior Uveitis Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anterior Uveitis Market Competitive Landscape And Company Profiles

• 30.1. Anterior Uveitis Market Competitive Landscape
• 30.2. Anterior Uveitis Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Aerie Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Anterior Uveitis Market Other Major And Innovative Companies

• 31.1. Regeneron Pharmaceuticals Inc.
• 31.2. UCB S.A.
• 31.3. Bausch & Lomb Incorporated
• 31.4. Cipla Ltd.
• 31.5. Hikma Pharmaceuticals PLC
• 31.6. Cadila Pharmaceuticals Ltd.
• 31.7. Santen Pharmaceutical Co. Ltd.
• 31.8. HanAll Biopharma Co. Ltd.
• 31.9. EyePoint Pharmaceuticals Inc.
• 31.10. Kiora Pharmaceuticals Inc.
• 31.11. Clearside Biomedical Inc.
• 31.12. Oculis SA
• 31.13. Aldeyra Therapeutics Inc.
• 31.14. Lux Biosciences Inc.
• 31.15. Tarsier Pharma Ltd.

32. Global Anterior Uveitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anterior Uveitis Market

34. Recent Developments In The Anterior Uveitis Market

35. Anterior Uveitis Market High Potential Countries, Segments and Strategies

• 35.1 Anterior Uveitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anterior Uveitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anterior Uveitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer